Standard Adjuvant Endocrine Therapy

Phase 3Small molecule

Standard Adjuvant Endocrine Therapy is one of 35 small molecule programs targeting Adjuvant. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdjuvantActive, not recruiting

Breast CancerActive, not recruiting

AdjuvantPhase 3

Active, not recruiting

Breast CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Standard Adjuvant Endocrine Therapy

Eli Lilly

Phase 3

1 2

Lexiscan

Astellas

Preclinical

1 3

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 4

Ablavar

LLantheus Medical Imaging

Preclinical

2 5

Naltrexone/bupropion

Novo Nordisk

Preclinical

1 6

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

1 7

Sertraline ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 8

Liposomal Irinotecan and Apatinib

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Preclinical

1 9

4SCAR T Cells

SShenzhen Geno-Immune Medical Institute

Preclinical

1 10

Ibrance

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Active, not recruiting

Adjuvant

NCT02513394

Q2 2029

Phase 3Active, not recruiting

Breast Cancer

NCT03155997

Clinical

Trials by Indication[1]

Adjuvant1 trial

PALbociclib CoLlaborative Adjuvant Study

Active, not recruiting·AAlliance Foundation Trials, LLC.·Phase 3·NCT02513394·5,796 enrolled

Breast Cancer1 trial

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT03155997·5,637 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Standard Adjuvant Endocrine Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Standard Adjuvant Endocrine Therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Standard Adjuvant Endocrine Therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Eli Lilly

Standard Adjuvant Endocrine Therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q2 2029

Trials by Indication[1]

Adjuvant1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News